About Laragen
Laragen is a company based in Culver City (United States) founded in 1995 was acquired by Transnetyx in August 2023. Laragen offers products and services including Sanger Sequencing, Mouse Genotyping, MiSeq Sequencing, Cell Line ID, and Fragment Analysis. Laragen operates in a competitive market with competitors including Omniome, HitGen, Rejuvenate Bio, Novogene Corporation and NovellusDx, among others.
- Headquarter Culver City, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Laragen, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Transnetyx
(Aug 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Laragen
Laragen offers a comprehensive portfolio of products and services, including Sanger Sequencing, Mouse Genotyping, MiSeq Sequencing, Cell Line ID, and Fragment Analysis.
High-quality DNA sequencing for academic and company projects.
Accurate testing for transgenic and knock-out mice research.
Advanced sequencing for metagenomic and genomic studies.
STR-based testing for human cell line verification.
Reliable PCR fragment analysis for genetic applications.
rDNA-based identification of bacteria and fungi.
Funding Insights of Laragen
Detailed funding history for Laragen
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Laragen
Laragen has secured backing from 1 investor. Prominent investors backing the company include Transnetyx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Automated genotyping services for murine cell lines are developed.
|
Locked | Locked | Locked |
Investor details for Laragen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Laragen
Investment portfolio details for Laragen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Laragen
Detailed financials for Laragen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Laragen Comparisons
Peer comparison for Laragen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Laragen
Laragen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, HitGen, Rejuvenate Bio, Novogene Corporation and NovellusDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA-encoded libraries are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Developer of technology for precision cancer diagnosis and therapies
|
|
| Locked | Locked | Locked |
Meta-genomics platforms and services for microbiome studies are provided.
|
Detailed competitors of Laragen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Laragen
Complete news archive for Laragen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laragen
Laragen was founded in 1995.
Laragen is headquartered in Culver City, United States. It is registered at Culver City, California, United States.
Laragen was founded in 1995 and is based in Culver City, United States. Genomic sequencing services are offered in the biotechnology sector, targeting both academic institutions and private companies. The portfolio encompasses Sanger sequencing, mouse genotyping, MiSeq sequencing, cell line identification, fragment analysis, microbial profiling, and identification services. Operations focus on reliable genetic analysis solutions across various applications.
Laragen's top competitors include Novogene Corporation, BGI and Omniome.
Laragen offers Sanger Sequencing, Mouse Genotyping, MiSeq Sequencing, Cell Line ID, and 2 more products and services.
Laragen has 1 investor. Key investors include Transnetyx.